Celemics

Celemics FCF/Debt

The Free Cash Flow to Debt Ratio of Celemics (331920.KQ) as of Oct 15, 2026 is -271.71 %. In the previous year, Free Cash Flow to Debt Ratio was -871.52 % — a change of -68.82% (higher).

FCF/Debt

-271.71 %

YoY

-68.82%

Last updated:

Free Cash Flow to Debt Ratio of Celemics is 2024 -271.71 % . Free Cash Flow to Debt Ratio of Celemics was 2023 -871.52 % . It decreases by -68.82% higher compared to the previous year.

The Celemics FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2017
-49.16 KRW
Jan 1, 2018
-35.10 KRW
Jan 1, 2019
-594.81 KRW
Jan 1, 2020
-24,845.99 KRW
Jan 1, 2021
-299.32 KRW
Jan 1, 2022
-523.15 KRW
Jan 1, 2023
-871.52 KRW
Jan 1, 2024
-271.71 KRW
The Celemics FCF/Debt history
YEARFCF/DebtYoY
-271.71 %-68.82%
-871.52 %+66.59%
-523.15 %+74.78%
-299.32 %-98.80%
-24,845.99 %+4,077.10%
-594.81 %+1,594.47%
-35.10 %-28.60%
-49.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celemics Stock analysis

What does Celemics do? Celemics Inc is a South Korean company based in Seoul, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company provides biotechnology services, focusing on the development and sale of target capture kit products. It also offers immune repertoire analysis solutions and next-generation sequencing solutions. Celemics Inc went public through an IPO on August 21, 2020, and currently employs 63 full-time staff. The company's products are sold in both domestic and international markets. Its headquarters are located in Seoul, South Korea, and it maintains a website at www.celemics.com. The firm's primary business activities include the provision of specialized biotechnology services, with an emphasis on innovative tools and solutions for life science research and applications. Celemics Inc has a presence in the Korean market and extends its reach to global customers, supporting various research and diagnostic needs through its technology-driven services. The company's operational focus remains on developing and delivering advanced biotechnology solutions to meet the evolving demands of the life sciences industry. Celemics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celemics stock

Free Cash Flow to Debt Ratio of Celemics is -271.71 % in 2024.

Free Cash Flow to Debt Ratio of Celemics changed from -871.52 % to -271.71 %, representing a -68.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Celemics since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Celemics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Celemics

All Key Metrics — Celemics